Drug profile · INN
lurasidone hydrochloride
LATUDA
lurasidone hydrochloride (LATUDA) is a serotonin 2a (5-ht2a) receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Drug details — lurasidone hydrochloride
- US status
- approved
- Class
- —
- Route
- ORAL
- Patents
- 0
- Programs
- 0
- Data quality
- 0.89
Quick answer
lurasidone hydrochloride (LATUDA) is a serotonin 2a (5-ht2a) receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
Key facts
Mechanism of action
Serotonin 2a (5-HT2a) receptor antagonist
Primary target: D(2) dopamine receptor
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
Related & competitor drugs
Frequently asked questions
What is lurasidone hydrochloride?
lurasidone hydrochloride (LATUDA) is a serotonin 2a (5-ht2a) receptor antagonist. Associated with Amneal Pharma Europe Ltd. Route of administration: oral. Current US regulatory status: approved.
What is the brand name for lurasidone hydrochloride?
LATUDA is a marketed brand name for lurasidone hydrochloride. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of lurasidone hydrochloride?
lurasidone hydrochloride has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.